(Sharecast News) - Novo Nordisk reported better-than-expected fourth quarter profit on the back of surging demand for its Wegovy weight loss drug but also said 2025 sales growth would slow slightly as competition for obesity treatments intensified.
Net profit at the Danish drug giant was up 29% to 28.23 billion Danish...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE